Can Fite BioPharma Ltd (CANF)

[midastouch017]

$CANF - Can-Fite BioPharma - Treatment for COVID-19 in clinical trials and more!

Catalyst

Can-Fite BioPharma (NYSE:CANF TASE:CFBI) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

The Company has an advanced pipeline of proprietary drug candidates in Phase II and III clinical development which address inflammatory, liver and metabolic diseases.

They have several potential catalysts:

Ongoing Phase II clinical trials: Piclidenoson for Treatment of COVID-19
https://clinicaltrials.gov/ct2/show/NCT04333472
Actual Study Start Date : January 6, 2021
Estimated Primary Completion Date : March 6, 2021

Upcoming Phase IIb study for Namodenoson drug candidate for non-alcoholic steatohepatitis (NASH) treatment
https://www.clinicaltrialsarena.com/news/can-fite-namodenoson-liver-cancer-trial/

Can-Fite plans Phase III liver cancer trial of Namodenoson in Europe
https://www.clinicaltrialsarena.com/news/can-fite-namodenoson-liver-cancer-trial/

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
https://ir.canfite.com/press-releases/detail/938/can-fite-announces-inhibition-of-liver-fibrosis-by-cannabis-compounds-in-preclinical-studies

Virtually no debt, market capitalization is close to cash value.

Analyst price target: $5 https://www.wsj.com/market-data/quotes/CANF/research-ratings